Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2003
04/03/2003WO2003026564A2 Pharmaceutical compositions for the treatment of urinary disorders
04/03/2003WO2003026563A2 Conjugated anti-psychotic drugs and uses thereof
04/03/2003WO2003026492A2 Prevention and treatment of restenosis by local administration of drug
04/03/2003WO2003026479A2 Methods of suppressing microglial activation
04/03/2003WO2003026444A1 Mixture of base-containing micronutrient substances
04/03/2003WO2003026420A1 Bactericidal solutions
04/03/2003WO2003013478A8 Method of encapsulating an active substance
04/03/2003WO2003011395A3 Method of utilizing neurotrophins to manipulate reproductive capacity
04/03/2003WO2003011295B1 Fexofenadine polymorph
04/03/2003WO2003007921A3 Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
04/03/2003WO2003002531A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2003002530A3 Pyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2003000269A3 Novel use for pde 10a inhibitors
04/03/2003WO2002102799A3 Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists
04/03/2003WO2002102766A3 Combretastatin a-3 prodrug
04/03/2003WO2002102313A3 Pyrimidine inhibitors of phosphodiesterase (pde) 7
04/03/2003WO2002100346A3 (r, r'),(r',s')-amphetaminil, compositions and uses thereof
04/03/2003WO2002100332A3 Isoxazoline compounds having mif antagonist activity
04/03/2003WO2002099052A3 Opns as modifiers of the p53 pathway and methods of use
04/03/2003WO2002099051A3 Nits as modifiers of the p53 pathway and methods of use
04/03/2003WO2002094270A3 Mip-1 alpha receptor ligands - drugs for t-cell mediated and autoimmune diseases
04/03/2003WO2002092563A3 Protease inhibitors
04/03/2003WO2002092049A3 System for delivering cosmetics and pharmaceuticals
04/03/2003WO2002092016A3 Therapeutic use of rank antagonists
04/03/2003WO2002090585A3 Genetic polymorphism pattern of tgfb1 as marker for susceptability to renal disease
04/03/2003WO2002089849B1 Compositions and delivery systems for administration of a local anesthetic agent
04/03/2003WO2002089736A3 Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
04/03/2003WO2002089729A3 Fused heterocyclic compounds
04/03/2003WO2002086078A3 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
04/03/2003WO2002085879B1 Three-step conversion of protected taxane ester to paclitaxel
04/03/2003WO2002085338A3 Ipratropium formulation for pulmonary inhalation
04/03/2003WO2002085312A3 Process for purifying 6-methoxy omeprazole
04/03/2003WO2002085297A3 Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
04/03/2003WO2002085296A3 Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
04/03/2003WO2002076460A3 Use of propentofylline to control intraocular pressure
04/03/2003WO2002076393A3 Antiagionecic, antitumor, chemopreventative agents
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002062330A3 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
04/03/2003WO2002062327B1 Method of treating neurological disorders using acetone derivatives
04/03/2003WO2002056753A3 P27 prevents cellular migration
04/03/2003WO2002045713A3 Orally-bioavailable formulations of fentanyl and congeners thereof
04/03/2003WO2002044419A3 Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
04/03/2003WO2002043731B1 Treatments for neurogenetic disorders, impulse control disorders, and wound healing
04/03/2003WO2002039954A3 Novel compounds
04/03/2003WO2002034248A3 METHOD FOR INCREASING TISSUE PERFUSION BY CO-ADMINISTRATION OF AN AGENT THAT INCREASES cGMP SYNTHESIS AND AN AGENT THAT INHIBITS cGMP DEGRADATION
04/03/2003WO2002032414A3 Ribavirin-pegylated interferon alfa hcv combination therapy
04/03/2003WO2002030404A3 Combination therapy for premenstrual symptoms
04/03/2003WO2002028380A3 Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
04/03/2003WO2002017852A3 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
04/03/2003WO2002015912A9 Compounds and methods for inhibiting neuronal cell death
04/03/2003WO2002013808A3 Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
04/03/2003WO2002012524A3 Adenovirus e1b-55k single amino acid mutants and methods of use
04/03/2003WO2002011698A9 Novel compositions of minoxidil
04/03/2003WO2002010214A3 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
04/03/2003WO2002007731A3 Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma
04/03/2003WO2000038618A3 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
04/03/2003US20030066097 Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
04/03/2003US20030065389 Polyacrylamide hydrogel for arthritis
04/03/2003US20030065382 Means and method for the treatment of coronary artery obstructions
04/03/2003US20030065377 Coated medical devices
04/03/2003US20030065330 Deflectable spacer for use as an interspinous process implant and method
04/03/2003US20030065229 Bactericides; oxidation resistance; antiinflammatory agents; antitumor agents
04/03/2003US20030065214 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
04/03/2003US20030065195 Ether compounds
04/03/2003US20030065186 Antihistamines, antiallergens, bronchodilator
04/03/2003US20030065179 Diabetic therapy
04/03/2003US20030065176 Anticoagulant; cardiovascular disorders
04/03/2003US20030065175 Novel heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them
04/03/2003US20030065174 Antiinflammatory agents; analgesics
04/03/2003US20030065173 Therapy for drug abuse
04/03/2003US20030065155 Probe for use as diagnostic tool in the detection of single nucleotide polymorphisms
04/03/2003US20030065146 Compound for use in the treatment of rheumatoid arthritis, osteoarthritis, inflammatory bowel disease and sepsis
04/03/2003US20030065040 Hypotensive agents
04/03/2003US20030065039 Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
04/03/2003US20030065038 Administering N-propargyl-1-aminoindan
04/03/2003US20030065036 Administering aminoguanidine
04/03/2003US20030065035 Crystallization using mixture of solvent and water
04/03/2003US20030065032 Topical applying of ointment
04/03/2003US20030065030 Containing carnosine; therapy for nervous system disorders
04/03/2003US20030065029 Agent for diagnosing and treating malignant tumors
04/03/2003US20030065028 Analgesic compositions comprising anti-epileptic compounds and methods of using same
04/03/2003US20030065027 Compositions for controlling microorganisms, comprising primary and secondary esters of polyglycerol in an effective ratio
04/03/2003US20030065026 Synergistic mixture with metal compound
04/03/2003US20030065025 Sponge-derived terpenoids and methods of use
04/03/2003US20030065023 Anticancer agents, viricides, psychological disorders
04/03/2003US20030065022 Mixture of paclitaxel and surfactant; anticancer agents
04/03/2003US20030065021 Tracheal smooth muscle relaxants
04/03/2003US20030065020 Treatment of macular degeneration
04/03/2003US20030065019 Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase
04/03/2003US20030065018 Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
04/03/2003US20030065017 Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists / antagonists, estrogens and progestins
04/03/2003US20030065016 Nordihydroguaiartic derivatives for use in treatment of tumors
04/03/2003US20030065015 Enzyme inhibitors; nervous system disorders
04/03/2003US20030065013 Central nervous system analgesic; hypotensive agents; antiarrhythmia agents; antidiabetic agents
04/03/2003US20030065012 Estrogen receptor modulators
04/03/2003US20030065011 Antiinflammatory agents, anticancer agents, antipyretics; side effect reduction
04/03/2003US20030065010 Preparation of anhydrous cetp inhibitor
04/03/2003US20030065008 Hormone replacement therapy; side effect reduction
04/03/2003US20030065007 Analgesics; psychological disorders; antidepressants
04/03/2003US20030065006 Viricides; anticancer agents
1 ... 5513 5514 5515 5516 5517 5518 5519 5520 5521 5522 5523 5524 5525 5526 5527 5528 5529 5530 5531 5532 5533 ... 7860